Make sure you register to access the on demand programme! #ESHCART2021

How I Manage CAR-T Therapies and Bispecific Antibodies
for my Patients

Chairs: Peter Borchmann, Ulrich Jäger, Marie José Kersten

September 6-9, 2021- E-Conference

FREE REGISTRATION

 

   

---

---

E-CONFERENCE SCIENTIFIC TOPICS

- Diffuse large B-cell Lymphoma: How to optimize the benefit of CAR T-cell therapy?
- Diffuse large B-cell Lymphoma: How to minimize potential risks of CAR T-cell therapy?
- Bispecific antibodies in the treatment of B-NHL
- Multiple Myeloma: targeting BCMA with bispecifics and CARs
- Acute lymphoblastic leukaemia: the role of CARs and bispecifics - lessons from paediatric haematology
- Perspectives: CARs and bispecifics for haematological malignancies

   


ABOUT THE CONFERENCE

About the programme:

CAR-T cells and bispecific antibodies have advanced our therapeutic armamentarium for haematological malignancies.
The programme of this ESH conference aims to provide an overview of the benefits and risks of currently available therapies for acute lymphoblastic leukaemia, lymphoma and multiple myeloma. Special focus will be placed on the advantages and disadvantages of bispecific antibodies vs. cellular therapies (including T cells, NK cells and transplant strategies). Future perspectives regarding applications in other haematological malignancies and in solid tumours will also be discussed.
The format of the meeting is based on the analysis and discussion of clinical case studies. It will adopt a problem-solving approach, addressing practical considerations and guidelines. Emphasis will be placed on open discussion, including a maximum level of interaction between faculty and registered participants.
In addition to the scientific and medical issues addressed during the conference, the questions of affordability of and access to these novel expensive treatments will be tackled by medical experts, representatives of patient organisations, economists, authorities and industry.

Learning objectives: Upon completion of this CME activity, participants should have improved understanding of:

1.  the current landscape of CAR-T cells and bispecific antibodies
2.  novel approaches and technologies in the field
3.  how to integrate these novel therapies into current clinical practice
4.  future perspectives in bispecific antibody and cellular therapies in haematological malignancies and solid tumours.

---

 

MEET THE EXPERT PROGRAMME

 

 

The How I Manage CAR-T Therapies and Bispecific Antibodies for My Patients E-Conference Meet the Expert sessions are live, interactive sessions that offer you an opportunity for informal dialogue with world authorities. The number of seats available is strictly limited, first come-first serve*. The sessions will not be recorded.
There will be no formal presentation. The Session Leaders are present to answer your questions and to provide you with expert guidance.

Registration Fee: 20 euros

*These sessions are open to academic biologists and clinicians only.    

---

   

With the support of*:

   

Major E-Conference Partners

*ESH conference programmes are developed in strict scientific independence
with no input from corporate sponsors